EUVIMEDEUVIMED entdecken
Crossref

Prostate artery embolization using n-butyl cyanoacrylate glue for symptomatic benign prostatic hyperplasia: A six-month outcome analysis in 103 patients

Romaric Loffroy, Alexis Quirantes, Kévin Guillen, Amin Mazit, Pierre-Olivier Comby, Ludwig Serge Aho-Glélé, Olivier Chevallier

Diagnostic and Interventional Imaging · 2024-04 · 105 (4) · 129-136

DOI: 10.1016/j.diii.2023.12.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostic and Interventional Imaging, 2024-04. Verfasst von Romaric Loffroy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 21079 Dijon, France; ICMUB Laboratory, UMR CNRS 6302, U…. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Enbucrilate, Embolization, Therapeutic, Lower Urinary Tract Symptoms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The purpose of this study was to assess the feasibility, safety, and 6-month outcomes of prostate artery embolization (PAE) using N-butyl-cyanoacrylate (NBCA) glue as the only embolic agent in patients with benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms. MATERIALS AND METHODS: Patients with BPH-related lower urinary tract symptoms who were treated by PAE using methacryloxysulfolane-NBCA mixed with ethiodized oil (1:8 ratio) between September 2018 and January 2023 were retrospectively included. Vascular mapping was made using cone-beam computed tomography angiography. PAEs were performed as an outpatient procedure, under local anaesthesia. Outcomes were assessed at six months using the International Prostate Symptoms Score (IPSS) and associated quality-of-life score (IPSS-QoL), prostate-specific antigen (PSA) level, prostate volume, and International Index of Erectile Function form 5 (IIEF5). RESULTS: A total of 103 men with a mean age of 68.4 ± 6 (standard deviation [SD]) years were included. Technical success rate was 100%. The mean fluoroscopy time was 26.4 ± 12.5 (SD) min and the median radiation dose was 23 980 mGy·cm (Q1, Q3: 16 770, 38 450). Compared to baseline, statistically significant improvements were observed at six months for the IPSS (8.9 ± 6.2 [SD] vs. 20.2 ± 6.5 [SD]; P = 0.01), IPSS-QoL (2.1 ± 1.4 [SD] vs. 5.1 ± 0.9 [SD]; P = 0.01), PSA level (3.6 ± 3.2 [SD] ng/mL vs. 4.8 ± 4.2 [SD] ng/mL; P = 0.0001), and prostate volume (78.6 ± 43.5 [SD] mL vs. 119.1 ± 65.7 [SD] mL; P = 0.01). Minor adverse events developed in 19/103 (18.4%) patients. No major complications occurred. Compared to baseline, the IIEF5 did not change significantly at six months (15.3 ± 6.8 [SD] vs. 15.8 ± 6.8 [SD]; P = 0.078). CONCLUSION: PAE with NBCA is a feasible and safe method that provides good outcomes at six months in patients with BPH-related lower urinary tract symptoms. This method deserves further evaluation in randomized trials with longer follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaEnbucrilateEmbolization, TherapeuticLower Urinary Tract SymptomsMaleHumansMiddle AgedAgedProstateProstate-Specific AntigenRetrospective StudiesQuality of LifeArteriesTreatment Outcome

Stichwörter der Autor:innen

Benign prostate hyperplasiaCyanoacrylatesLower urinary tract symptomsOutcome studiesProstate artery embolization

Substanzen

EnbucrilateProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 21079 Dijon, France; ICMUB Laboratory, UMR CNRS 6302, Université de Bourgogne, 210000 Dijon, France. Electronic address: roma…
  • Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 21079 Dijon, France.
  • Department of Vascular and Interventional Radiology, François-Mitterrand University Hospital, 21079 Dijon, France; ICMUB Laboratory, UMR CNRS 6302, Université de Bourgogne, 210000 Dijon, France.
  • ICMUB Laboratory, UMR CNRS 6302, Université de Bourgogne, 210000 Dijon, France; Department of Neuroradiology and Emergency Radiology, François-Mitterrand University Hospital, 21079 Dijon, France.
  • Department of Epidemiology, Statistics and Clinical Research, François-Mitterrand University Hospital, 21079 Dijon, France.

Zitieren

APA

Loffroy, R., Quirantes, A., Guillen, K., Mazit, A., Comby, P. O., Aho-Glélé, L. S., & Chevallier, O. (2024). Prostate artery embolization using n-butyl cyanoacrylate glue for symptomatic benign prostatic hyperplasia: A six-month outcome analysis in 103 patients. Diagnostic and Interventional Imaging, 105(4), 129-136. https://doi.org/10.1016/j.diii.2023.12.006

Vancouver

Loffroy R, Quirantes A, Guillen K, Mazit A, Comby PO, Aho-Glélé LS, et al. Prostate artery embolization using n-butyl cyanoacrylate glue for symptomatic benign prostatic hyperplasia: A six-month outcome analysis in 103 patients. Diagnostic and Interventional Imaging. 2024;105(4):129-136. doi:10.1016/j.diii.2023.12.006

BibTeX
@article{Loffroy2024,
  author = {Loffroy, Romaric and Quirantes, Alexis and Guillen, Kévin and Mazit, Amin and Comby, Pierre-Olivier and Aho-Glélé, Ludwig Serge and Chevallier, Olivier},
  title = {Prostate artery embolization using n-butyl cyanoacrylate glue for symptomatic benign prostatic hyperplasia: A six-month outcome analysis in 103 patients},
  journal = {Diagnostic and Interventional Imaging},
  year = {2024},
  volume = {105},
  number = {4},
  pages = {129--136},
  doi = {10.1016/j.diii.2023.12.006}
}
Kostenlos starten →